Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
pCPA File Number:
21591
Negotiation Status:
Concluded with an LOI
Indication(s):
Cystic Fibrosis, F508del CFTR mutation
Sponsor/Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
CDA-AMC Project Number:
SR0673
pCPA Engagement Letter Issued:
Negotiation Process Concluded: